TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc., (Amex: ADL) a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, announced that the AMDL-ELISA DR- 70(R) (FDP) test has been shown to be a useful test for the detection of cancer in clinical practice according to an independent study of 185 patients from the Medical Department II at the University Hospital in Frankfurt Germany. The results were published in the international medical research publication Alimentary Pharmacology & Therapeutics.
The purpose of this independent study was to evaluate the potential of the DR-70 ELISA (FDP) test as a detection test for gastrointestinal cancers that include, colorectal, esophageal, gallbladder, gastric, liver, pancreatic and intestinal cancers. Additionally, the quantitative value of DR-70 (FDP) was tested as a parameter for the progression of these cancers. Serum samples were taken from a total of 80 cancer patients with histologically proven malignant tumors and 100 healthy blood donors in this study. Patients with colorectal cancer were also tested for carcinoembryogenic antigen (CEA), a competing diagnostic test to AMDL-ELISA DR-70 (FDP). The complete article about AMDL-ELISA DR-70 (FDP) can be accessed via AMDL's corporate website located at http://www.amdl.com under the RESOURCES link.
"When we compared the DR-70 immunoassay with conventional tumor
markers, DR-70 turned out to be superior to CEA in the detection of
patients with colorectal cancer," according to the conclusion of authors.
The authors also concluded that DR-70 (FDP) levels were shown to b
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved